^Offertáler L, Mo FM, Bátkai S, et al. Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Molecular Pharmacology. March 2003, 63 (3): 699–705. PMID 12606780. doi:10.1124/mol.63.3.699.
^Schuelert N, McDougall JJ. The abnormal cannabidiol analogue O-1602 reduces nociception in a rat model of acute arthritis via the putative cannabinoid receptor GPR55. Neuroscience Letters. August 2011, 500 (1): 72–6. PMID 21683763. S2CID 3410391. doi:10.1016/j.neulet.2011.06.004.
^Szczesniak AM, Maor Y, Robertson H, et al. Nonpsychotropic cannabinoids, abnormal cannabidiol and canabigerol-dimethyl heptyl, act at novel cannabinoid receptors to reduce intraocular pressure. Journal of Ocular Pharmacology and Therapeutics. October 2011, 27 (5): 427–35. PMID 21770780. doi:10.1089/jop.2011.0041.